CXCL9 and neoplasm: Mechanistically, it has been proposed that EZH2-mediated gene silencing of chemokines, such as CXCL9 and CXCL10, prevents effector T-cell trafficking to the tumor microenvironment, thereby allowing tumor cells to evade immunity [101].